This table lists all the major pharma collaborations, acquisitions and mergers agreed during June 2014.
For an indepth analysis of these deals, read ‘Pharma deals during June 2014’
|
Licensor acquired / licensee acquirer |
Deal type |
Product / technology |
Headline ($m) |
| Covidien/ Medtronic | Company acquisition | Medical device company adding US critical mass | 42,900 |
| Idenix Pharmaceuticals/ Merck & Co | Company acquisition | Hepatitis C assets include IDX21437 (p1/2 nucleotide inhibitor) to combine with Merck HCV drugs | 3,850 |
| Labrys Biologics/ Teva | Company acquisition | Includes Labrys’ p2b anti-CGRP mAb for treatment of episodic migraine | 825 |
| Chelsea Therapeutics/ Lundbeck | Company acquisition | Includes Northera (droxidopa) for neurogenic orthostatic hypotension (approved) | 658 |
| OAO Veropharm/ Abbott Laboratories | Company acquisition | Russian based manufacturing company | 630 |
| DAVA Pharmaceuticals/ Endo International | Company acquisition | Generics business including generic Doxycycline and Cefdinir | 575 |
| Bionomics/ Merck & Co | Exclusive research and licence agreement | BNC 375 in Alzheimer’s disease (preclinical) | 526 |
| Adaptimmune/ GSK | Co-development and option | TCR engineered T-cells which target NY-ESO-1 and other targets in oncology (p1/2) | 350 |
| Genia Technologies/ Roche | Company acquisition | Single molecule, semiconductor, DNA sequencing using nanopore technology | 350 |
| Medreich/ Meiji Seika | Company acquisition | India-based manufacturing company | 290 |
| Cellectis/ Pfizer | Collaboration | Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies directed at multiple selected oncology targets (platform) | 265* + $28m equity |
| Dimension Therapeutics/ Bayer | Licence | Gene therapy for the treatment of haemophilia A (preclinical) | 252 |
| Synairgen/ AstraZeneca | Exclusive global licence | SNG 001 inhaled beta interferon (p2) | 232 |
| Ligand Pharmaceuticals/ TG Therapeutics | Exclusive global licence | Development, commercialisation of Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) inhibitors (preclinical) | 208 |
| Pregenen/ bluebird bio | Company acquisition | Gene editing technology platform | 156 |
| OraSure Technologies/ AbbVie | Co-promotion** | ODM-201, an investigational novel oral androgen receptor inhibitor (p2) | 75 |
| Orion/ Bayer | Co-development, option to co-promote in Europe | OraQuick HCV rapid test in US | 68 |
| Sorrento Therapeutics / Morphotek | Research and option agreement | To generate chemotherapeutic antibody drug conjugates (ADCs) (platform) | 50 |
| NanoString Technologies/ Celgene | Development | Development of a companion diagnostic assay | 45 |
| ECR Pharmaceuticals / Valeant | Company acquisition | Akorn subsidiary with branded generics business | 41 |
All deals are worldwide unless otherwise noted.
* Deal terms included up to $185m milestones per product; estimated headline could be approximately $2.8bn if all products are successful.
**US only